MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

2.250 -0.040 (-1.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
From Enveric Biosciences
Via Business Wire
News headline image
SmallCap Emerge: ENVB, SMX, ANY, ELPW Across High-Growth Sectors
Via AB Newswire
Topics Artificial Intelligence Economy
News headline image
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
From Enveric Biosciences
Via Business Wire
News headline image
Kartoon Studios (NYSE: TOON) Gaining Momentum Alongside CMND, ENVB, WLDS, ANY – See Why?
Via AB Newswire
Topics Intellectual Property
News headline image
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Registration of Five Trademarks
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Patent Issuance
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
From Enveric Biosciences, Inc
Via Business Wire
News headline image
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Reverse Stock Split
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
From Enveric Biosciences
Via Business Wire
News headline image
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
News headline image
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story